– the leading provider of online annual reports to individual and institutional investors.

Agennix AG

Agennix AG, a biopharmaceutical company, engages in developing therapies in the areas of unmet medical needs to improve the length and quality of life of seriously ill patients primarily in Germany and the United States. The company’s lead program, talactoferrin, is an oral targeted therapy in Phase III clinical development for the treatment of severe sepsis and non-small cell lung cancer.

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports